Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers

Idenix Shareholder Sues to Block $3.9 Billion Merck Deal

Idenix Pharmaceuticals Inc. is undervalued by Merck & Co.’s $3.9 billion takeover offer, a shareholder said in a lawsuit seeking to block the deal.

Merck, based in Whitehouse Station, New Jersey, said June 9 that it would acquire Idenix to expand its experimental pipeline for hepatitis C treatments. The proposed purchase price of $24.50 a share is more than triple Cambridge, Massachusetts-based Idenix’s closing level on June 6 of $7.23.

Merck is paying the highest premium on record for any health-care deal of at least $100 million, according to data compiled by Bloomberg. The price still fails to account for Idenix’s “intrinsic value” and resulted from a flawed process that prevents competing bids, investor Ronald Burns claimed in a complaint filed today in Delaware Chancery Court.

The deal includes a no-solicitation clause, grants Merck the right to match any superior offer and provides for a $115.6 million termination fee, according to the complaint. By accepting those terms, Idenix directors have “locked up” a sale to Merck, Burns said.

About 170 million people worldwide are infected with hepatitis C, a chronic disease caused by a virus that attacks the liver. Idenix’s lead drug, IDX21437, works by stopping the hepatitis C virus from replicating within the body.

The case is Burns v. Idenix Pharmaceuticals Inc., CA9764, Delaware Chancery Court (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.